Navidea Biopharmaceuticals (NAVB) says it's entered into an agreement with Nordion (NDZ -1%) to...

|About: Navidea Biopharmaceuticals (NAVB)|By:, SA News Editor

Navidea Biopharmaceuticals (NAVB) says it's entered into an agreement with Nordion (NDZ -1%) to produce and supply its (123) labeled I-drug NAV5001 for late-phase clinical trials. NDZ will manufacture and supply of NAV5001 clinical trial material by radiolabeling NAVB's precursor drug product with Iodine-123 to form (123)I NAV5001, and then manage the logistics and shipping arrangements to third-party clinical trial sites. The agreement could be a precursor to a commercial supply arrangement in the future.